Radionuclide therapy via SSTR: future aspects from experimental animal studies

Neuroendocrinology
Eva Forssell-AronssonHåkan Ahlman

Abstract

There is need for better therapeutic options for neuroendocrine tumours. The aim of this review was to summarize results of experimental animal studies and raise ideas for future radionuclide therapy based on high expression of somatostatin (SS) receptors by many neuroendocrine tumours. In summary, one of the major options is individualized treatment for each patient, including choice of SS analogues, radionuclides and treatment schedules. Other options are methods to increase the treatment effect on tumour tissue (increasing tumour uptake and retention by upregulation of receptor expression and avoiding saturation of receptor binding), methods to increase the tumour tissue response (by choice of radionuclides, SS analogues or combined therapies), and methods to reduce side effects (diminished uptake and retention in critical organs and reduced normal tissue response). Furthermore, combination therapy with other radiopharmaceuticals, cytotoxic drugs or radiosensitizers can be considered to enhance the effects of radiolabelled SS analogues.

References

Aug 1, 1979·Cancer Letters·D S LongneckerW Noll
Mar 1, 1991·International Journal of Radiation Oncology, Biology, Physics·K D Schupak, K E Wallner
Mar 1, 1986·International Journal of Radiation Oncology, Biology, Physics·W E SamlowskiW T Sause
Jun 1, 1987·International Journal of Radiation Oncology, Biology, Physics·R A AbramsJ F Wilson
Dec 1, 1987·International Journal of Radiation Oncology, Biology, Physics·J S MsirikaleS E Order
Nov 1, 1981·International Journal of Radiation Oncology, Biology, Physics·T J KeaneB J Cummings
Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C G Moertel
Jan 1, 1981·Cancer Chemotherapy and Pharmacology·A L Harris
Sep 15, 1994·Annals of the New York Academy of Sciences·B N Kimmig
Jan 21, 1993·International Journal of Cancer. Journal International Du Cancer·A C MillerD Samid
Jan 1, 1993·Life Sciences·P A Eden, J E Taylor
Jan 17, 1996·International Journal of Cancer. Journal International Du Cancer·P O ZamoraF F Knapp
May 20, 1998·International Journal of Radiation Biology·J E MoulderE P Cohen
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Mar 18, 1999·The New England Journal of Medicine·M H Kulke, R J Mayer
May 18, 1999·International Journal of Cancer. Journal International Du Cancer·G D SlooterC H van Eijck
Sep 1, 1999·Clinical Endocrinology·D G Wang
Nov 7, 1999·European Journal of Nuclear Medicine·A OtteJ Muller
Aug 6, 2000·Cell and Tissue Research·M Verheij, H Bartelink
Feb 22, 2001·Nuclear Medicine and Biology·P BernhardtE Forssell-Aronsson
Apr 27, 2001·Nuclear Medicine and Biology·J E BugajA Srinivasan
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·M de JongE P Krenning
Oct 24, 2001·Acta Oncologica·P BernhardtG Skarnemark
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·H ZhouT K Hei
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·J S LewisC J Anderson
Apr 30, 2002·Pediatric Research·Asa SvenssonRolf Christofferson
Jun 18, 2002·Journal of Cellular and Molecular Medicine·N Shinomiya
Aug 15, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Dorothee Twardella, Jenny Chang-Claude
Sep 19, 2002·Bioconjugate Chemistry·Margret SchotteliusMarkus Schwaiger
Nov 27, 2002·European Journal of Pharmacology·Jean Claude ReubiHelmut R Mäcke
Dec 11, 2002·Kidney International·Carlton M BatesSandy Grady
Dec 13, 2002·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Erik I Christensen, Pierre J Verroust
Dec 17, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Edgar J RollemanEric P Krenning
Feb 6, 2003·International Journal of Cancer. Journal International Du Cancer·Wouter A P BreemanMarion de Jong

❮ Previous
Next ❯

Citations

Apr 14, 2016·Nuclear Medicine and Biology·Christian MaaßGerhard Glatting
Aug 27, 2014·Nuclear Medicine and Biology·Emil SchülerEva Forssell-Aronsson
Jan 18, 2014·Nuclear Medicine and Biology·Emil SchülerEva Forssell-Aronsson
Feb 16, 2018·Endocrine-related Cancer·Tobias HofvingOla Nilsson
Nov 15, 2019·PloS One·Viktor SandblomEva Forssell-Aronsson
Mar 31, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Charlotte K AnderssonEva B Forssell-Aronsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis